Development of Injectable Formulation of 4’-O-benzyloxycarbonyl-etoposide Derivative Based on Human Serum Albumin for the Chemotherapy of Breast Cancer

Development of Injectable Formulation of 4’-O-benzyloxycarbonyl-etoposide Derivative Based on Human Serum Albumin for the Chemotherapy of Breast Cancer

Introduction. One of the promising strategies for the development of injectable formulations of poorly water-soluble drugs is the preparation of their nanosuspensions stabilized with albumin. A well-known example of the successful implementation of this technology is Abraxane® (nanoparticle albumin-...

Full description

Saved in:
Bibliographic Details
Main Authors: T. S. Kovshova, S. A. Boiko, M. A. Merkulova, N. S. Osipova, N. I. Moiseeva, Ju. A. Malinovskaya, S. N. Mantrov, S. E. Gelperina
Format: Article
Language:Russian
Published: LLC Center of Pharmaceutical Analytics (LLC «CPHA») 2023-09-01
Series:Разработка и регистрация лекарственных средств
Subjects:
etoposide prodrug
human serum albumin
nanoparticles
cytotoxicity
breast cancer
Online Access:https://www.pharmjournal.ru/jour/article/view/1541
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.pharmjournal.ru/jour/article/view/1541

Similar Items